Trial Search Results

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

This is a long-term study in cystic fibrosis patients who are participating in the Cystic Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of the large intestine). Patients will be followed at their regular clinical care visits over a 10-year period and approached if they develop symptoms of fibrosing colonopathy for collection and use of further detailed information.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Collaborator: Forest Research Institute, Inc., an Allergan affiliate

Stanford Investigator(s):

Intervention(s):

  • Biological: CREON
  • Biological: ZENPEP
  • Biological: ULTRESA
  • Biological: PANCREAZE
  • Biological: PERTZYE
  • Biological: other non-sponsor pancreatic enzyme replacement therapy
  • Other: No pancreatic enzyme replacement therapy

Eligibility


Inclusion Criteria:

The inclusion criteria for enrollment in the Base Study Population

   - Diagnosed with cystic fibrosis,

   - Enrolled in the Cystic Fibrosis Patient Registry

   - Receiving medical care at a Cystic Fibrosis Foundation-accredited care center
   providing data to the Cystic Fibrosis Patient Registry

Exclusion Criteria:

Ages Eligible for Study

N/A - 99 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Carlos Milla
650) 723-8325, (650) 736-9824
Recruiting